Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A low-cost generic version of Truvada as PrEP will hit the market September 30.
Fact-checkers and HIV advocates break down the president’s State of the Union boasts.
The FDA has found a probable cancer-causing contaminant in generic drugs shipped from abroad––most recently, Zantac (ranitidine).
At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.
The head of the Food and Drug Administration cited a long commute and time away from family as reasons to step down.
Stocks of drug companies are rising—and that’s not a good sign for consumers.
The FDA commissioner wants drugmakers to “end the shenanigans.”
Scott Gottlieb has said he wants lower costs and faster drug approvals.
New HCV treatment boasts over 90 percent cure rates, costs $84,000 in the United States, and is being distributed at 1 percent of the cost.
The Irish pharmaceutical company Actavis has agreed to buy out rival New York CityÃ¢€“based Forest Laboratories.
In November 2011, Pfizer will lose a $10 billion a year revenue stream when the patent on one of its best-selling drugs, Lipitor, expires and...
Advocates from several nongovernmental organizations are calling on the Mexican government to declare a “national HIV/AIDS emergencyR...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.